Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference
- 4 September 2018
- journal article
- review article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 26 (3-4) , 59-73
Abstract
The 11th International Oncolytic Virus Conference (IOVC) was held from April 9–12, 2018 in Oxford, UK. This is part of the high-profile academic-led series of meetings that was started back in 2002 by Steve Russell and John Bell, with most of the previous meetings being held in North America (often in Banff). The conference brought together many of the major players in oncolytic virotherapy from all over the world, addressing all stages of research and development—from aspects of basic science and cellular immunology all the way through to early- and late-phase clinical trials. The meeting welcomed 352 delegates from 24 countries. The top seven delegate countries, namely, the UK, US, Canada, The Netherlands, Germany, Japan and South Korea, contributed 291 delegates while smaller numbers coming from Australia, Austria, Bulgaria, China, Finland, France, Iraq, Ireland, Israel, Italy, Latvia, Malaysia, Poland, Slovenia, Spain, Sweden and Switzerland. Academics comprised about half of the attendees, industry 30% and students 20%. The next IOVC is scheduled to be held on Vancouver Island in autumn 2019. Here we share brief summaries of the oral presentations from invited speakers and proffered papers in the different subtopics presented at IOVC 2018.Keywords
This publication has 63 references indexed in Scilit:
- The evolutionary history of lethal metastatic prostate cancerNature, 2015
- Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemiaLeukemia, 2015
- Safety and Efficacy of VCN-01, an Oncolytic Adenovirus Combining Fiber HSG-Binding Domain Replacement with RGD and Hyaluronidase ExpressionClinical Cancer Research, 2015
- Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissueNature Genetics, 2015
- Diverse roles of STING-dependent signaling on the development of cancerOncogene, 2015
- Oncolytic parvoviruses: from basic virology to clinical applicationsVirology Journal, 2015
- Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic VirusMolecular Therapy, 2014
- Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograftInternational Journal of Cancer, 2014
- Remission of Disseminated Cancer After Systemic Oncolytic VirotherapyMayo Clinic Proceedings, 2014
- Engineering of Bacteria for the Visualization of Targeted Delivery of a Cytolytic Anticancer AgentMolecular Therapy, 2013